Suspension of trading

Spexis AG Share Price Swiss Exchange

Stocks

POLN

CH0106213793

Pharmaceuticals

OTC Markets Traded
Delayed Swiss Exchange 10:06:37 19/03/2025 pm IST 5-day change 1st Jan Change
0.0100 CHF -75.00% Intraday chart for Spexis AG -75.00% -84.62%
3 months-82.46%
6 months-77.58%
1 week-75.00%
3 months-82.46%
6 months-77.58%
Current year-84.62%
1 week 0.01
Extreme 0.01
0.04
1 month 0.01
Extreme 0.01
0.06
3 years 0.01
Extreme 0.01
1.35
5 years 0.01
Extreme 0.01
9.45
Manager TitleAgeSince
Chief Executive Officer 64 31/03/2022
Director of Finance/CFO - 01/08/2024
Director TitleAgeSince
Chairman 70 20/11/2019
Director/Board Member 65 01/06/2013
Director/Board Member 80 30/12/2021
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-75.00%-88.89%-99.22% 8L
+1.04%+10.52%+34.86%+0.28% 7.67TCr
+0.74%+6.41%+26.31%+188.91% 5.05TCr
+1.02%+0.81%-7.73%+21.83% 4.85TCr
+1.30%+3.46%-50.91%-49.51% 4.41TCr
-0.87%-1.24%+55.49%-23.16% 3.05TCr
-0.66%-5.74%+54.13%+88.28% 2.43TCr
-1.29%+3.24%+104.79%-48.00% 2.25TCr
+0.78%+3.23%-7.24%+213.08% 2TCr
-0.10%-1.86%+66.61%+162.37% 1.6TCr
Average +0.21%-0.38%+18.74%+45.48% 3.7TCr
Weighted average by Cap. +0.50%+0.67%+23.01%+46.99%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B